ARVO

David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.

Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution

Research being presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, is examining novel interventions that could address the growth in myopia.

At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.

With the progression of MS, thinning of the retinal ganglion cell (RGC) complex is seen as well as a decrease in the amplitude of the pattern electroretinogram (pERG)

More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.

Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations at the ARVO annual conference in Seattle, Washington.

Annual conference to kick off May 5 in Emerald City.

Diana V. Do, MD, presented details of the PHOTON study at the Association for Research in Vision and Ophthalmology annual meeting, held recently in New Orleans, highlighting the safety and efficacy of 8 milligrams of aflibercept.

Vivek Srinivasan, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation about using visible light, OCT to image the retina at this year's ARVO meeting.

Ravi Parikh, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation about adopting dropless cataract surgery to help reduce cost to both patients and the healthcare system at this year's ARVO meeting.

Nazlee Zebardast, MD, MSc sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her research on using machine learning methods to identify image-based, specifically OCT based, phenotypes or structural phenotypes for glaucoma. at this year's ARVO meeting.

Eric Mikula, PhD, from ViaLase sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss the company's femtosecond laser image-guided high-precision trabeculectomy, FLigHT, for non-incisional glaucoma treatment at this year's ARVO meeting.

Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.

Ophthalmology Times® talked with Carlos Ciller, PhD, the co-founder and CEO of RetinAI, about technological advances the company is making to drive innovation and to accelerate drug development pipelines at this year's ARVO meeting.

Ophthalmology Times® talked with Kaustubh Ghosh, PhD, about lysyl oxidase, a recently discovered molecule that causes the blood vessels in the eye to become stiffer at this year's ARVO meeting.

Ophthalmology Times® talked with Alfonso Sabater, MD, PhD where he discusses a patient case of his with epidermolysis bullosa at this year's ARVO meeting.

Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year's ARVO meeting.

Ophthalmology Times® talked with Darius Moshfeghi, MD, about BUTTERFLEYE data trial results using aflibercept versus laser for the treatment of retinopathy of prematurity this year's ARVO meeting.

Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.

Ophthalmology Times® talked Nevin El-Nimri, MS, OD, PhD, FAAO, about the relationship between optic disc fovea distance, axial length and disc at this year's ARVO meeting.

Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.

Ophthalmology Times® talked with Theresa Heath, MD, MBA, about Non-viral gene therapy targeting ABCA4 retinopathies at this year's ARVO meeting.

Ophthalmology Times® talked with Michael Ip, MD, about the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.at this year's ARVO meeting.

Ophthalmology Times® talked with David Brown, MD, about the PHOTON study examining the safety and efficacy of high-dose aflibercept for the treatment of diabetic macular edema (DME) at this year's ARVO meeting.

Ophthalmology Times® talked with Allen Chiang, MD, about the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials at this year's ARVO meeting.

Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.